Erbitux Solution For Injection 100Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Erbitux: Solution for injection (100mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

CETUXIMAB (se TUX i mab) is a chemotherapy drug. It targets a specific protein within cancer cells and stops the cells from growing. It is used to treat colorectal cancer and head and neck cancer.

In-Depth Information

Erbitux 100mg/50ml Solution for Injection

NDC: 667330948
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Colorectal Cancer, Head And Neck Cancer

Sometimes used for but not FDA approved for the following conditions:
Non-small Cell Lung Cancer (NSCLC)

Storage Information
Refrigerate (between 36 and 46 degrees F)
Preparations of product in infusion containers are stable up to 12 hours at 36 to 46 degrees F and up to 8 hours at 68 to 77 degrees F
Discard unused portion. Do not store for later use.
Do not freeze
Erbitux 100mg/50ml Solution for Injection

Reported Side Effects for Erbitux 100mg/50ml Solution for Injection

Itching Incidence:
<2.0%*
Severity: SEVERE
Onset: RAPID
Chills Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Headache Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Kidney Failure Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
1.0-3.0%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
1.0-2.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
1.0-3.0%*
Severity: SEVERE
Onset: EARLY
Infection Incidence:
1.0-11.0%*
Severity: SEVERE
Onset: DELAYED
Conjunctivitis Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Nervousness Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Weight Loss Incidence:
1.0-11.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
2.0-6.0%*
Severity: SEVERE
Onset: EARLY
Not Breathing Incidence:
2.0%*
Severity: SEVERE
Onset: RAPID
Acne Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Drug-Induced Acne Incidence:
2.0-18.0%*
Severity: SEVERE
Onset: DELAYED
Infusion-related Reactions Incidence:
2.0-5.0%*
Severity: SEVERE
Onset: RAPID
Vomiting Incidence:
2.0-5.0%*
Severity: SEVERE
Onset: EARLY
Suddenly Stopped Heart Incidence:
2.0-3.0%*
Severity: SEVERE
Onset: EARLY
Cough Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
2.0-22.0%*
Severity: SEVERE
Onset: EARLY
Decreased Appetite Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Joint Pain Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Sore Throat Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Constipation Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Weakness Incidence:
4.0-16.0%*
Severity: SEVERE
Onset: DELAYED
Bone Pain Incidence:
4.0%*
Severity: SEVERE
Onset: DELAYED
Dehydration Incidence:
5.0-6.0%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Low Magnesium Levels Incidence:
6.0-17.0%*
Severity: SEVERE
Onset: DELAYED
Confusion Incidence:
6.0%*
Severity: SEVERE
Onset: EARLY
Skin Rash Incidence:
9.0-16.0%*
Severity: SEVERE
Onset: EARLY
Dry Mouth Incidence:
12.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
14.0-16.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
14.0%*
Severity: MODERATE
Onset: DELAYED
Hand And Foot Syndrome Incidence:
15.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
16.0%*
Severity: SEVERE
Onset: EARLY
Feeling Sick Incidence:
16.0%*
Severity: SEVERE
Onset: EARLY
Low White Blood Cell Counts Incidence:
17.0%*
Severity: SEVERE
Onset: DELAYED
Dry Skin Incidence:
22.0-57.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
31.0%*
Severity: SEVERE
Onset: EARLY
Low White Blood Cells Incidence:
31.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Erbitux

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5